<?xml version="1.0" encoding="UTF-8"?>
<collection xmlns="http://www.loc.gov/MARC21/slim">
 <record>
  <leader>     caa a22        4500</leader>
  <controlfield tag="001">469078197</controlfield>
  <controlfield tag="003">CHVBK</controlfield>
  <controlfield tag="005">20180323132941.0</controlfield>
  <controlfield tag="007">cr unu---uuuuu</controlfield>
  <controlfield tag="008">170328e19920901xx      s     000 0 eng  </controlfield>
  <datafield tag="024" ind1="7" ind2="0">
   <subfield code="a">10.1007/BF00173535</subfield>
   <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="035" ind1=" " ind2=" ">
   <subfield code="a">(NATIONALLICENCE)springer-10.1007/BF00173535</subfield>
  </datafield>
  <datafield tag="245" ind1="0" ind2="0">
   <subfield code="a">5-HT1D binding sites in various species: similar pharmacological profile in dog, monkey, calf, guinea-pig and human brain membranes</subfield>
   <subfield code="h">[Elektronische Daten]</subfield>
   <subfield code="c">[Anne Bruinvels, Hugues Lery, Joachim Nozulak, Jose Palacios, Daniel Hoyer]</subfield>
  </datafield>
  <datafield tag="520" ind1="3" ind2=" ">
   <subfield code="a">Summary: Radioligand binding studies were performed in membranes of calf caudate, guinea-pig cortex, dog caudate and whole brain, monkey caudate and whole brain, and human caudate using the novel iodinated radioligand, Serotonin-5-O-Carboxymethyl-Glycyl[125I] Tyrosinamide (abbreviated [125I]GTI for the sake of simplicity), a ligand known to label 5-HT 1B and 5-HT 1D sites. In all membrane preparations tested, [125I]GTI labelled high affinity sites with the following rank order of affinity: 5-carboxamidotryptamine &gt; 5-HT = DHE = ergotamine &gt;- sumatriptan &gt;- metergoline = CGS 12066 &gt;- yohimbine = methysergide &gt;- methiothepin &gt; 8-OHDPAT &gt;_ mianserin &gt;- CP 93129 &gt;- (−)pindolol = ketanserin &gt;_ isamoltane = mesulergine &gt;- corynanthine = spiperone &gt; MDL 72222. The affinity profiles were very similar in the membranes of the different species, especially in dog, monkey and human brain. The pharmacological profile of [1251]GTI binding (determined with up to 25 different drugs) was fully comparable to the binding profile reported previously in human substantia nigra (using [1251]GTI) or in a variety of brain preparations known to contain 5-HTID sites using [3H]5-HT as a radioligand. Although, the affinity profiles obtained in the various preparations displayed statistically highly significant correlations with slope values close to one, some drugs displayed slight species-related variations in affinity, as already reported in rabbit brain (see Xiong and Nelson 1989; Hoyer et al. 1992, accompanying report). The present report 1) establishes for the first time the pharmacological profile of 5-HT1D sites in dog and monkey brain, 2) shows that the pharmacological characteristics of these sites is indeed very similar in the brain of a variety of species including man, and 3) demonstrates the advantageous features of [1251]GTI as an iodinated 5-HT1D radioligand which can be used without the need to mask the binding to other 5-HT receptor subtypes.</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
   <subfield code="a">Springer-Verlag, 1992</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">[125I]GTI</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">5-HTID receptors</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Calf</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Guinea-pig</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Dog</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Monkey</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Human brain</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Bruinvels</subfield>
   <subfield code="D">Anne</subfield>
   <subfield code="u">Preclinical Research, 360/604, Sandoz Pharma Ltd, CH-4002, Basel, Switzerland</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Lery</subfield>
   <subfield code="D">Hugues</subfield>
   <subfield code="u">Preclinical Research, 360/604, Sandoz Pharma Ltd, CH-4002, Basel, Switzerland</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Nozulak</subfield>
   <subfield code="D">Joachim</subfield>
   <subfield code="u">Preclinical Research, 360/604, Sandoz Pharma Ltd, CH-4002, Basel, Switzerland</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Palacios</subfield>
   <subfield code="D">Jose</subfield>
   <subfield code="u">Preclinical Research, 360/604, Sandoz Pharma Ltd, CH-4002, Basel, Switzerland</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Hoyer</subfield>
   <subfield code="D">Daniel</subfield>
   <subfield code="u">Preclinical Research, 360/604, Sandoz Pharma Ltd, CH-4002, Basel, Switzerland</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="773" ind1="0" ind2=" ">
   <subfield code="t">Naunyn-Schmiedeberg's Archives of Pharmacology</subfield>
   <subfield code="d">Springer-Verlag</subfield>
   <subfield code="g">346/3(1992-09-01), 243-248</subfield>
   <subfield code="x">0028-1298</subfield>
   <subfield code="q">346:3&lt;243</subfield>
   <subfield code="1">1992</subfield>
   <subfield code="2">346</subfield>
   <subfield code="o">210</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2="0">
   <subfield code="u">https://doi.org/10.1007/BF00173535</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="908" ind1=" " ind2=" ">
   <subfield code="D">1</subfield>
   <subfield code="a">research-article</subfield>
   <subfield code="2">jats</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">856</subfield>
   <subfield code="E">40</subfield>
   <subfield code="u">https://doi.org/10.1007/BF00173535</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Bruinvels</subfield>
   <subfield code="D">Anne</subfield>
   <subfield code="u">Preclinical Research, 360/604, Sandoz Pharma Ltd, CH-4002, Basel, Switzerland</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Lery</subfield>
   <subfield code="D">Hugues</subfield>
   <subfield code="u">Preclinical Research, 360/604, Sandoz Pharma Ltd, CH-4002, Basel, Switzerland</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Nozulak</subfield>
   <subfield code="D">Joachim</subfield>
   <subfield code="u">Preclinical Research, 360/604, Sandoz Pharma Ltd, CH-4002, Basel, Switzerland</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Palacios</subfield>
   <subfield code="D">Jose</subfield>
   <subfield code="u">Preclinical Research, 360/604, Sandoz Pharma Ltd, CH-4002, Basel, Switzerland</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Hoyer</subfield>
   <subfield code="D">Daniel</subfield>
   <subfield code="u">Preclinical Research, 360/604, Sandoz Pharma Ltd, CH-4002, Basel, Switzerland</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">773</subfield>
   <subfield code="E">0-</subfield>
   <subfield code="t">Naunyn-Schmiedeberg's Archives of Pharmacology</subfield>
   <subfield code="d">Springer-Verlag</subfield>
   <subfield code="g">346/3(1992-09-01), 243-248</subfield>
   <subfield code="x">0028-1298</subfield>
   <subfield code="q">346:3&lt;243</subfield>
   <subfield code="1">1992</subfield>
   <subfield code="2">346</subfield>
   <subfield code="o">210</subfield>
  </datafield>
  <datafield tag="900" ind1=" " ind2="7">
   <subfield code="a">Metadata rights reserved</subfield>
   <subfield code="b">Springer special CC-BY-NC licence</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="898" ind1=" " ind2=" ">
   <subfield code="a">BK010053</subfield>
   <subfield code="b">XK010053</subfield>
   <subfield code="c">XK010000</subfield>
  </datafield>
  <datafield tag="949" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="F">NATIONALLICENCE</subfield>
   <subfield code="b">NL-springer</subfield>
  </datafield>
 </record>
</collection>
